Fig 1.

Study design for alemtuzumab for myelodysplastic syndrome. Patients received a 10-day infusion of alemtuzumab as described in Patients and Methods. Follow-up visits and assessment for response were performed at 3, 6, and 12 months. IV, intravenous; CsA, cyclosporine.